Skip to main content

Table 1 Baseline characteristics and NTRK3 promotor methylation status among all patients with CRC in validation cohort

From: Genome-wide analysis identifies critical DNA methylations within NTRKs genes in colorectal cancer

Variables

Total

NTRK3 promotor methylation

P value

Hypomethylation

Hypermethylation

Age (median = 62 years)

 < 62

111

100

11

 

 ≥ 62

118

103

15

0.504

Sex

 Female

100

88

12

 

 Male

129

115

14

0.786

Tumor localization

 Colon

126

114

12

 

 Rectum

103

89

14

0.334

Tumor size (median = 4.5 cm)

 < 4.5

104

90

14

 

 ≥ 4.5

123

111

12

0.382

 Unknown

2

   

Tumor differentiation

 High or moderate

191

168

23

 

 Poor

38

35

3

0.584

Lymphovascular invasion

 No

210

188

22

 

 Yes

17

13

4

0.219

 Unknown

2

   

Perineural invasion

 No

208

183

25

 

 Yes

19

18

1

0.611

 Unknown

2

   

TNM stage

 I–II

143

123

20

 

 III–IV

85

79

6

0.112

 Unknown

1

   

CIMP

 Negative

222

198

24

 

 Positive

7

5

2

0.145

Microsatellite status

 MSS

125

113

12

 

 MSI

51

39

12

0.015

 Unknown

53

   

KRAS

 Wild-type

119

110

9

 

 Mutation

62

46

16

0.001

 Unknown

48

   

BRAF

 Wild-type

174

151

23

 

 Mutation

8

6

2

0.674

 Unknown

47

   

Ki-67

 ≤ 25%

100

89

11

 

 > 25%

84

72

12

0.502

 Unknown

45

   

CA19-9

 ≤ 37

179

160

19

 

 > 37

32

29

3

0.833

 Unknown

18

   

CEA

 ≤ 5

158

138

20

 

 > 5

57

54

3

0.122

 Unknown

14

   
  1. CIMP: CpG island methylator phenotype; KRAS: kirsten rat sarcoma viral oncogene; BRAF: B-Raf proto-oncogene, serine/threonine kinase; Ki-67: kiel67 antigen; CA19-9: carbohydrate antigen 19-9; CEA: carcinoembryonic antigen